A Big Pharma Sex Tape Compounds China Woes
China is widely viewed as a critical global growth market and the pharmaceutical industry sees it no different. Unfortunately for GlaxoSmithKline (NYSE: GSK) the pursuit of increased revenue has led to allegations of a massive $489 million bribery scheme. In the wake of that announcement Glaxo's sales in the Middle Kingdom dipped dramatically and its plans to more than double China's importance to 10% of overall sales by 2018 may prove challenging.
The newest rumored twists in this scandal involves politically connected corporate whistle blowing and a sex tape featuring Glaxo's former China head Mark Reilly that was sent to the pharma's senior management including CEO Andrew Witty. As the story gains tabloid traction, it continues to shine an unwanted light on the company's sales tactics, which are being investigated by the UK's Serious Fraud Office, and in a number of countries.
In this episode of Where the Money Is, health care analysts David Williamson and Michael Douglass discuss the latest twists in turns in China, the investigations surrounding Glaxo's marketing, and what it all means for investors.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article A Big Pharma Sex Tape Compounds China Woes originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.